Clinical Trial

A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of Part 1 of this clinical research study is to find the highest tolerable dose of cladribine that can be given in combination with low dose cytarabine (LDAC) and venetoclax to patients who have AML. The goal of Part 2 of this clinical research study is to learn if the dose of cladribine found in Part 1, when combined with LDAC and venetoclax, can help to control the disease.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-30.
Trial Details
NCT Number NCT07053020
Lead Sponsor M.D. Anderson Cancer Center
Conditions Acute Myeloid Leukemia (AML)
Enrollment 58 participants
Start Date 2027-12-01
Primary Completion 2028-06-30 (estimated)
Study Completion 2030-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-14